subtilisin


Also found in: Dictionary, Wikipedia.
Related to subtilisin: trypsin

sub·til·i·sin

(sŭb-til'ĭ'sin),
A proteinase produced by Bacillus subtilis and other species, similar to the serine proteinases of other molds and bacteria; it catalyzes the hydrolysis of a few specific peptide bonds in certain proteins, converting chymotrypsinogen to chymotrypsin and ovalbumin to plakalbumin in this manner, and cleaves pancreatic ribonuclease into S-peptide and S-protein.
Synonym(s): subtilopeptidase

subtilisin

(sŭb-tĭl′ĭ-sĭn)
n.
Any of several extracellular enzymes produced by bacteria of the genus Bacillus that catalyze the breakdown of proteins into polypeptides and are widely used in detergents and cleaning products.
References in periodicals archive ?
Fasting induces hyperlipidemia in mice overexpressing proprotein convertase subtilisin kexin type 9: lack of modulation of very-low-density lipoprotein hepatic output by the low-density lipoprotein receptor.
cDNA cloning and heterologous expression of a wheat proteinase inhibitor of subtilisin and chymotrypsin (WSCI) that interferes with digestive enzymes of insect pests.
KEY WORDS: Perkinsus marinus, subtilisin, serine protease, real-time PCR, Crassostrea virginica, Crassostrea gigas, Crassostrea ariakensis
Nevertheless, Chen and Arnold [9] have adapted enzymes to these environments by improving the activity of Subtilisin E by three cycles of error-prone PCR to obtain an enzyme that is 256 times more efficient than the native parent in a solution containing 60 percent DMF.
subtilisin (3), chymosin (4), and interleukin-1[beta] ( 5).
In nature, subtilisin breaks apart the chains of amino acids that make up certain proteins.
In the case of PrioCHECK Trichinella AAD, this enzyme is a subtilisin.
Lipids: All eyes are on ongoing pivotal phase III randomized clinical outcome trials of three monoclonal antibodies that inhibit proprotein convertase subtilisin kexin type 9 (PCSK9): the 22,500-patient FOURIER trial of evolocumab, which includes 9,000 patients older than 65 years; the 18,000-patient ODYSSEY Outcomes trial of alirocumab; and the SPIRE-1 and SPIRE-2 trials of bococizumab totaling 18,300 patients.
Russell and co-worker Darrell Williams converted the enzyme subtilisin into a "biomonomer" that can link up with other monomers.
OSLER (Open-Label Study of Long-Term Evaluation Against LDL Cholesterol) included 4,465 patients who had completed one of a dozen earlier phase II or III studies of evolocumab, a monoclonal antibody that inhibits proprotein convertase subtilisin kexin type 9 (PCSK9), and were then randomized 2:1 to 1 year of open-label evolocumab administered subcutaneously at either 140 mg every 2 weeks or 420 mg once monthly plus standard lipid lowering, or to standard lipid lowering alone, generally with moderate- or highdose statins.
Circulating proprotein convertase subtilisin kexin type 9 has a diurnal rhythm synchronous with cholesterol synthesis and is reduced by fasting in humans.
REPATHA(TM) is an antibody that targets PCSK9 (proprotein convertase subtilisin kexin type 9), a protein that reduces the liver's ability to remove low-density lipoprotein cholesterol (LDL-C) from the blood.